Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 20/20 | 0.62 |
| ▸ | HDAC2 known ✓ | Q92769 | 11/20 | 0.62 |
| ▸ | HDAC3 known ✓ | O15379 | 10/20 | 0.62 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 8/20 | 0.62 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 8/20 | 0.62 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 8/20 | 0.62 |
| ▸ | HDAC4 known ✓ | P56524 | 7/20 | 0.62 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 7/20 | 0.62 |
| ▸ | HDAC10 known ✓ | Q969S8 | 7/20 | 0.62 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 7/20 | 0.62 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 7/20 | 0.62 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | KDM1A | O60341 | 1/20 | 0.62 |
| ▸ | F3 | P13726 | 1/20 | 0.62 |
| ▸ | NAMPT | P43490 | 3/20 | 0.55 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL302457 | 0.99 | HDAC1 (0.63) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| Bromide SCHEMBL2409900 | 0.98 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL2411926 | 0.91 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL3559032 | 0.89 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL2412810 | 0.88 | HDAC1 (0.55) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL2413630 | 0.87 | HDAC1 (0.66) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL2416256 | 0.87 | HDAC1 (0.66) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL2411259 | 0.87 | HDAC1 (0.56) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL2416730 | 0.86 | HDAC1 (0.50) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL2410013 | 0.86 | HDAC1 (0.67) | HDAC1HDAC2HDAC3HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018176-B2 | Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-28 | — | — | US | disclosed |
| US-8026239-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-27 | — | — | US | disclosed |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-07 | — | — | US | disclosed |
| EP-2170330-A1 | SYNERGISTIC COMBINATION OF ANTHRANILAMIDE PYRIDINUREAS AND BENZAMIDE DERIVATIVES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-07 | — | — | EP | disclosed |
| CN-101686970-A | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives | BAYER SCHERING PHARMA AG | 2010-03-31 | — | — | CN | disclosed |
| US-7687525-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-30 | — | — | US | disclosed |
| US-20090048292-A1 | SYNERGISTIC COMBINATION | BAYER SCHERING PHARMA AG (DE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009000558-A1 | SYNERGISTIC COMBINATION OF ANTHRANILAMIDE PYRIDINUREAS AND BENZAMIDE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-31 | — | — | WO | disclosed |
| EP-2008658-A1 | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-12-31 | — | — | EP | disclosed |
| US-20080188489-A1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-08-07 | — | — | US | disclosed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | disclosed |
| WO-2005007158-A1 | TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-01-27 | — | — | WO | disclosed |
| US-6841565-B1 | Benzamide derivatives which induce apoptosis in inactive, non-proliferating B-CLL cells | THE OHIO STATE UNIVERSITY (US) | 2005-01-11 | — | — | US | disclosed |
| US-6794392-B1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | SCHERING AKTIENGESELLSCHAFT | 2004-07-29 | — | — | US | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| EP-1437346-A1 | Benzamide derivatives useful as cell differentiation inducers | Schering AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-0847992-B1 | Benzamide derivatives, useful as cell differentiation inducers | SCHERING AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| US-6174905-B1 | AS CARCINOSTATIC AGENT TO A HEMATOLOGIC MALIGNANCY AND A SOLID CARCINOMA | MITSUI CHEMICALS, INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0847992-A1 | Benzamide derivatives, useful as cell differentiation inducers | Mitsui Chemicals, Inc. (JP) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188489-A1 | Cell differentiation inducer | MCL1, MYADM, MYD88 | HDAC1 150/4885HDAC2 170/4885HDAC3 618/4885 |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | MCL1, MYADM, PDCD1 | HDAC1 81/4885HDAC2 204/4885HDAC3 807/4885 |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | MCL1, MYADM, MYD88 | HDAC1 163/4885HDAC2 183/4885HDAC3 680/4885 |
| US-20050054647-A1 | New pharmaceutical combination | VEGFA, INHA, PGF | HDAC1 976/4885HDAC2 1101/4885HDAC3 1616/4885 |
| US-20090048292-A1 | SYNERGISTIC COMBINATION | HDAC1, HDAC2, HDAC11 | HDAC1 1/4885HDAC2 2/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.